Morquio

Mor·qui·o

(mōr'kyō),
References in periodicals archive ?
Daniel, 16, who suffers from Morquio's Syndrome, was left quadriplegic following complications during surgery close to his spinal cord.
5 February 2010 - US-based BioMarin Pharmaceutical Inc (NASDAQ: BMRN) gave an update yesterday on the Phase I/II study for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome.
At age three, Ian was diagnosed with Morquio syndrome, also known as mucopolysaccharidosis (MPS) type IVA.
M2 EQUITYBITES-March 9, 2012-BioMarin Pharmaceutical Inc enrols patients for Phase 3 study of GALNS for Morquio A Syndrome(C)2012 M2 COMMUNICATIONS http://www.m2.com
Daniel, who suffers from the rare Morquio's Syndrome, was left quadriplegic following surgery at the Royal Manchester Children's Hospital last year.
The group are ditching their uniforms to help 16-year-old Daniel Woodhouse, who suffers from a rare genetic condition called Morquio's Syndrome.
The 15-year-old, from Stainton, suffers from Morquio's Syndrome - a rare genetic disorder which has affected his growth and led to mobility problems.
The teenager, from Stainton, suffers from Morquio's Syndrome - a rare genetic disorder which affected his growth and led to mobility problems.
The 15-year-old suffers from Morquio's Syndrome, a rare genetic disorder which stops the skeleton growing.
Odiparcil has also the potential to address other MPS types, characterized by the accumulation of chondroitin or dermatan sulfate (MPS I or Hurler/Sheie syndrome, MPS II or Hunter syndrome, MPS IVa or Morquio syndrome and MPS VII or Sly syndrome).
(NASDAQ: BMRN) announced today that Vimizim[R] (elosulfase alfa) has been approved by the National Medical Products Administration (NMPA) for the treatment of patients with mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome.
Clinical review report: elosulfase alfa (Vimizim) (2 mg/kg of body weight) for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis IVA (Morquio A syndrome, or MPS IVA) [Internet].